All In Biotech

Drug Trial Radar · NCT04121676

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Sep 26, 2019

Primary completion

Feb 22, 2024

Study completion Nov 30, 2024

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.

Conditions

  • Advanced Cancer

Interventions

  • AGEN2373Drug

    An Anti-CD137 Monoclonal Antibody

  • BotensilimabDrug

    Anti-CTLA-4 Monoclonal Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicity (DLT)Time frame: First 28 days of treatment Q2W and Q4W and First 21 days Q3W
  2. Frequency of treatment-emergent adverse events (TEAEs)Time frame: Screening to 90 days from last dose
  3. Severity of treatment-emergent adverse events (TEAEs)Time frame: Screening to 90 days from last dose
  4. Duration of treatment-emergent adverse events (TEAEs)Time frame: Screening to 90 days from last dose

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California Norris Comprehensive Cancer Center/ Hoag

    Los Angeles, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Miami

    Coral Gables, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Atlantic Health System

    Morristown, New Jersey

  • Roswell Park Comprehensive Cancer Care

    Buffalo, New York

  • Columbia University

    New York, New York

  • Providence Cancer Institute

    Portland, Oregon

  • UPMC

    Pittsburgh, Pennsylvania

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • NEXT Oncology

    San Antonio, Texas

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.